EUVIMEDEUVIMED entdecken
Open Access

Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia

Martti Vanker, Karita Särekannu iD, Arnaud Fekkar, Sofie Eg Jørgensen, Liis Haljasmägi, Anne Kallaste, Kalle Kisand, Margus Lember, Pärt Peterson, Madhvi Menon, Tracy Hussell, Sean Knight und 9 weitere

Journal of Interferon & Cytokine Research · 2023-09 · 43 (9) · 379-393

DOI: 10.1089/jir.2023.0003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Interferon & Cytokine Research, online erschienen am 15.09.2023. Verfasst von Martti Vanker und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedicine and Translational Medicine; Institute of Clinical Medicine; University of Tartu, Tartu, Estonia. Hauptthemen laut MEDLINE: COVID-19, Interferon Type I. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, Howard Hughes Medical Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoantibodies (AABs) neutralizing type I interferons (IFN) underlie about 15% of cases of critical coronavirus disease 2019 (COVID-19) pneumonia. The impact of autoimmunity toward type III IFNs remains unexplored. We included samples from 1,002 patients with COVID-19 (50% with severe disease) and 1,489 SARS-CoV-2-naive individuals. We studied the prevalence and neutralizing capacity of AABs toward IFNλ and IFNα. Luciferase-based immunoprecipitation method was applied using pooled IFNα (subtypes 1, 2, 8, and 21) or pooled IFNλ1–IFNλ3 as antigens, followed by reporter cell-based neutralization assay. In the SARS-CoV-2-naive cohort, IFNλ AABs were more common (8.5%) than those targeting IFNα2 (2.9%) and were related with older age. In the COVID-19 cohort the presence of autoreactivity to IFNλ did not associate with severe disease [odds ratio (OR) 0.84; 95% confidence interval (CI) 0.40–1.73], unlike to IFNα (OR 4.88; 95% CI 2.40–11.06; P < 0.001). Most IFNλ AAB-positive COVID-19 samples (67%) did not neutralize any of the 3 IFNλ subtypes. Pan-IFNλ neutralization occurred in 5 patients (0.50%), who all suffered from severe COVID-19 pneumonia, and 4 of them neutralized IFNα2 in addition to IFNλ. Overall, AABs to type III IFNs are rarely neutralizing, and do not seem to predispose to severe COVID-19 pneumonia on their own.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Interferon Type IHumansInterferon LambdaSARS-CoV-2AutoantibodiesInterferon-alphaInterferons

Stichwörter der Autor:innen

COVID-19autoantibodiestype I interferonstype III interferons

Substanzen

Interferon LambdaAutoantibodiesInterferon-alphaInterferon Type IInterferons

Autor:innen und Institutionen

  • Institute of Biomedicine and Translational Medicine; Institute of Clinical Medicine; University of Tartu, Tartu, Estonia.
  • Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Service de Parasitologie-Mycologie, Groupe Hospitalier Pitié Salpêtrière, AP-HP, Paris, France.
  • Department of Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark.
  • Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
  • Department of Internal Medicine, Tartu University Hospital, Tartu, Estonia.

ORCID-Profile: Karita Särekannu, Kai Kisand

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • Howard Hughes Medical Institute

Zitieren

APA

Vanker, M., Särekannu, K., Fekkar, A., Jørgensen, S. E., Haljasmägi, L., Kallaste, A., Kisand, K., Lember, M., Peterson, P., Menon, M., Hussell, T., Knight, S., Moore-Stanley, J., Bastard, P., Zhang, S. Y., Mogensen, T. H., Philippot, Q., Zhang, Q., Puel, A., …, & Kisand, K. (2023). Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia. Journal of Interferon & Cytokine Research, 43(9), 379-393. https://doi.org/10.1089/jir.2023.0003

Vancouver

Vanker M, Särekannu K, Fekkar A, Jørgensen SE, Haljasmägi L, Kallaste A, et al. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia. Journal of Interferon & Cytokine Research. 2023;43(9):379-393. doi:10.1089/jir.2023.0003

BibTeX
@article{Vanker2023,
  author = {Vanker, Martti and Särekannu, Karita and Fekkar, Arnaud and Jørgensen, Sofie Eg and Haljasmägi, Liis and Kallaste, Anne and Kisand, Kalle and Lember, Margus and Peterson, Pärt and Menon, Madhvi and Hussell, Tracy and Knight, Sean and Moore-Stanley, James and Bastard, Paul and Zhang, Shen-Ying and Mogensen, Trine H and Philippot, Quentin and Zhang, Qian and Puel, Anne and Casanova, Jean-Laurent and Kisand, Kai},
  title = {Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia},
  journal = {Journal of Interferon & Cytokine Research},
  year = {2023},
  volume = {43},
  number = {9},
  pages = {379--393},
  doi = {10.1089/jir.2023.0003}
}
Kostenlos starten →